<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Chronic lymphocytic leukemia is one of the most common types of leukemia in adults. It belongs to the group of indolent lymphoproliferative disorders and has a slow clinical course. Approximately 50% of newly diagnosed patients do not require treatment for years. A better understanding of the pathophysiology of the disease has led to the development of models for assessment of the risk.</p><p>Our study aimed to evaluate the prognostic significance of the serum marker beta-2 microglobulin (82M) and the flow cytometric marker CD49d in patients with early-stage of B-chronic lymphocytic leukemia (B-CLL) as well as look for a correlation between CD 49d and the early stages of the disease. For this purpose, analysis of 30 untreated patients with known and newly diagnosed B-CLL was carried out. The following methods were used: documentary, flow cytometric analysis of peripheral blood, Rai staging system and chi-square test of independence (Fisher’s Exact Test). The results from our study showed that a small number of patients in the early stage of the disease have high levels of CD49d expression and beta-2 microglobulins. In eight of 29 patients, the flow cytometric marker was higher than 30%, and in ten out of 29 patients, the B2M was above the reference range. No significant correlation between the two markers in early stage B-CLL patients was found.</p></abstract>

Chronic lymphocytic leukemia is one of the most common types of leukemia in adults. It belongs to the group of indolent lymphoproliferative disorders and has a slow clinical course. Approximately 50% of newly diagnosed patients do not require treatment for years. A better understanding of the pathophysiology of the disease has led to the development of models for assessment of the risk.Our study aimed to evaluate the prognostic significance of the serum marker beta-2 microglobulin (82M) and the flow cytometric marker CD49d in patients with early-stage of B-chronic lymphocytic leukemia (B-CLL) as well as look for a correlation between CD 49d and the early stages of the disease. For this purpose, analysis of 30 untreated patients with known and newly diagnosed B-CLL was carried out. The following methods were used: documentary, flow cytometric analysis of peripheral blood, Rai staging system and chi-square test of independence (Fisher’s Exact Test). The results from our study showed that a small number of patients in the early stage of the disease have high levels of CD49d expression and beta-2 microglobulins. In eight of 29 patients, the flow cytometric marker was higher than 30%, and in ten out of 29 patients, the B2M was above the reference range. No significant correlation between the two markers in early stage B-CLL patients was found.

Prognostic Biomarkers in Early-Stage B-CLL Patients

Department of Clinical Laboratory, Clinical Immunology and Allergology

Department of Physics and Biophysics, Preclinical and Clinical Sciences

Journal of Biomedical and Clinical Research

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"Prognostic Biomarkers in Early-Stage B-CLL Patients"}

Chronic lymphocytic leukemia is one of the most common types of leukemia in adults. It belongs to the group of indolent lymphoproliferative disorders and has a...

Prognostic Biomarkers in Early-Stage B-CLL Patients

Publié en ligne: 30 juin 2018

Pages: 135 - 139

Reçu: 24 nov. 2017

Accepté: 27 févr. 2018

DOI: https://doi.org/10.1515/jbcr-2017-0022

Mots clés
microglobulin, leukemia, stage, Rai, risk

© 2017 Vanya S. Popova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Prognostic Biomarkers in Early-Stage B-CLL Patients

Publié en ligne: 30 juin 2018

Pages: 135 - 139

Reçu: 24 nov. 2017

Accepté: 27 févr. 2018

DOI: https://doi.org/10.1515/jbcr-2017-0022

Mots clésmicroglobulin, leukemia, stage, Rai, risk

© 2017 Vanya S. Popova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Mots clés
microglobulin, leukemia, stage, Rai, risk